Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Advertisement
International news in seven languages
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.